Azilect Patent Expiration

Azilect is a drug owned by Teva Neuroscience Inc. It is protected by 5 US drug patents filed in 2013. Out of these, 2 drug patents are active and 3 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 27, 2027. Details of Azilect's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire.
US7815942 Rasagiline formulations of improved content uniformity
Aug, 2027

(2 years from now)

Active
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572834 Rasagiline formulations and processes for their preparation
Dec, 2026

(2 years from now)

Active
US5453446 Use of the R-enantiomers of N-propargyl 1-aminoindan compounds for treating Parkinson's disease.
Feb, 2017

(7 years ago)

Expired
US6126968 Stable compositions containing N-propargyl-1-aminoindan
Sep, 2016

(8 years ago)

Expired
US5532415 R-enantiomer of N-propargyl-1-aminoindan, salts, compositions and uses thereof
Jul, 2013

(11 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Azilect's patents.

Given below is the list of recent legal activities going on the following patents of Azilect.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Year, Large Entity 13 Apr, 2022 US7815942
Expire Patent 13 Sep, 2021 US7572834
Maintenance Fee Reminder Mailed 29 Mar, 2021 US7572834
Payment of Maintenance Fee, 8th Year, Large Entity 10 Apr, 2018 US7815942
Patent Issue Date Used in PTA Calculation 19 Oct, 2010 US7815942
Recordation of Patent Grant Mailed 19 Oct, 2010 US7815942
Issue Notification Mailed 29 Sep, 2010 US7815942
Dispatch to FDC 17 Sep, 2010 US7815942
Issue Fee Payment Received 13 Sep, 2010 US7815942
Issue Fee Payment Verified 13 Sep, 2010 US7815942


FDA has granted several exclusivities to Azilect. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Azilect, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Azilect.

Exclusivity Information

Azilect holds 1 exclusivities. All of its exclusivities have expired in 2017. Details of Azilect's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-685) May 29, 2017

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Several oppositions have been filed on Azilect's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Azilect's generic, the next section provides detailed information on ongoing and past EP oppositions related to Azilect patents.

Azilect's Oppositions Filed in EPO

Azilect has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 13, 2017, by Generics (U.K.) Limited. This opposition was filed on patent number EP06720975A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP06720975A Feb, 2017 Generics (U.K.) Limited Patent maintained as amended


US patents provide insights into the exclusivity only within the United States, but Azilect is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Azilect's family patents as well as insights into ongoing legal events on those patents.

Azilect's Family Patents

Azilect has patent protection in a total of 18 countries. It's US patent count contributes only to 14.8% of its total global patent coverage. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Azilect.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Azilect's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Aug 27, 2027 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Azilect Generics:

Rasagiline Mesylate is the generic name for the brand Azilect. 11 different companies have already filed for the generic of Azilect, with Alkem Labs Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Azilect's generic

Alternative Brands for Azilect

Azilect which is used for managing the symptoms of Parkinson's disease., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Bausch
Tasmar Used for managing symptoms of Parkinson's disease.
Boehringer Ingelheim
Mirapex Er Used for managing symptoms of Parkinson's disease.
Impax
Rytary Used for treating Parkinson's disease and related conditions such as post-encephalitic parkinsonism and parkinsonism from carbon monoxide or manganese intoxication.
Orion Pharma
Comtan Used for treating Parkinson's disease.
Stalevo 50 Used for managing symptoms of Parkinson's disease.
Stalevo 75 Used for managing symptoms of Parkinson's Disease.
Stalevo 100 Used for managing symptoms of Parkinson's disease.
Stalevo 125 used for managing symptoms of Parkinson's Disease.
Stalevo 150 Used for managing symptoms of Parkinson's disease.
Stalevo 200 Used for managing the symptoms of Parkinson's disease.
Supernus Pharms
Osmolex Er Used for treating Parkinson's disease and drug-induced extrapyramidal reactions in adult patients.





About Azilect

Azilect is a drug owned by Teva Neuroscience Inc. It is used for managing the symptoms of Parkinson's disease. Azilect uses Rasagiline Mesylate as an active ingredient. Azilect was launched by Teva in 2006.

Approval Date:

Azilect was approved by FDA for market use on 16 May, 2006.

Active Ingredient:

Azilect uses Rasagiline Mesylate as the active ingredient. Check out other Drugs and Companies using Rasagiline Mesylate ingredient

Treatment:

Azilect is used for managing the symptoms of Parkinson's disease.

Dosage:

Azilect is available in tablet form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
EQ 0.5MG BASE TABLET Prescription ORAL
EQ 1MG BASE TABLET Prescription ORAL